there in terms of understanding the need and what tools can we bring in the clinical trials and research programs to enhance that. I think technology is going to be able to at least support the identification of people to enhance that outreach, and we want to make sure these opportunities ...
会议名称:Clinical trials with targeted therapies in CLL 背景 CLL14研究显示,在既往未经治疗的慢性淋巴细胞白血病(CLL)和共存疾病患者中,与苯丁酸氮芥联合obinutuzumab(Clb-Obi)相比,维奈克拉(venetoclax)联合obinutuzumab(Ven-Obi)显著改善...
8. ClinicalTrials gov. NCT04608318. Available at: https://www.clinicaltrials.gov/ct2/show/NCT04608318 (accessed August 2021). 9. DCLLSG. CLL17 Trial. Available at: https://www.ocllsg.de/en/trial/cll17/CLL17_Synop...
Clinical Decision-Making With PERSIST-2: Optimizing Therapy for Anemic Myelofibrosis Patients With Splenomegaly Optimizing Myelofibrosis Therapy: A Comprehensive Comparison of JAK Inhibitor Clinical Trials From Design to Outcomes A 74-Year-Old Patient Newly Diagnosed with BPDCN ...
[2] A study of zanubrutinib (BGB-3111) versus ibrutinib in participants with relapsed/refractory chronic lymphocytic leukemia. ClinicalTrials.gov. Accessed September 25, 2022. https://clinicaltrials.gov/ct2/show/NCT03734016 [3] Opat S, Tedeschi A, Linton K, et al. The MAGNOLIA Trial: Zan...
Nicole Lamanna, MD, highlights various clinical trials underway evaluating new treatment options for patients with chronic lymphocytic leukemia. Chronic Lymphocytic Leukemia An emerging need in the chronic lymphocytic leukemia (CLL) population is the progression observed with covalent BTK inhibitors and ...
Data on COVID-19 management strategies collected included use of supplemental oxygen, mechanical ventilation, hemodialysis, antiviral therapies, lopinavir/ritonavir, hydroxychloroquine, remdesivir, corticosteroid, tocilizumab, convalescent plasma, and/or other agents on clinical trials. The primary study end ...
Impressive data update of orelabrutinib. At the first national lymphocytedisease academic conference of Chinese Medical Association (中华医学会第一次全国淋巴细胞疾病学术大会) held on 16-18 Apr 2021, InnoCare releasedorelabrutinib’s updated clinical data in a phase I/II (part II) study (NCT034...
The next step is using CLL-TIM for patient selection in the investigator-initiated, randomized phase 2–3 trial within the Nordic and the Hovon CLL study groups, the PreVent-ACaLL trial (clinicaltrials.gov: NCT03868722). This trial investigates whether three months of acalabrutinib and venetocla...
As monotherapy, molecularly targeted therapies, such as BTK inhibitors and venetoclax, are cornerstone therapies for patients with CLL. Although clinical trials of the combination of ibrutinib and venetoclax are ongoing, it was observed that anatomic compartments determine tumor cell sensitivity. More...